Study characterizes unique immune response in patients who experience inflammatory arthritis as side effect of cancer therapies
Immune checkpoint inhibitor (ICI) therapies used to treat cancer come with the risk of adverse autoimmune responses, including arthritis that can persist for years and require joint replacement surgery. Little is known about the specific cells responsible for these events. Researchers at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, and collaborators led a study to investigate these immune adverse events and identified a specific type of CD8 T cell that characterizes inflammatory arthritis induced by ICI therapies.
Researchers ...











